deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT07059299

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma (NeoTISLEGA)

NeoTISLEGA - A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

Sponsor: BeiGene

Conditions Esophageal Adenocarcinoma Esophagogastric Junction Adenocarcinoma Gastric Adenocarcinoma Neoadjuvant Therapy Resectable Esophagogastric Adenocarcinoma
Interventions FLOT Chemotherapy Tislelizumab
Updated 2 times since 2025 Last updated: Dec 12, 2025 Started: Dec 12, 2025 Primary completion: Aug 31, 2027 Completion: Aug 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07059299, this PHASE1 trial focuses on Esophageal Adenocarcinoma and Esophagogastric Junction Adenocarcinoma and remains actively recruiting participants. Sponsored by BeiGene, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2025 – ~Jan 2026 · 5 months · monthly snapshotNot Yet Recruiting~Jan 2026 – present · 8 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  2. Aug 2025 — Jan 2026 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeiGene
  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
  • Universitätsklinikum Leipzig
Data source: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations